How Viruses Affect Particular Organs?
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled. Glycoprotein and
glycolipid patterns on the surfaces of cells provide many viruses with a means
of entrance. In the human body, HIV and hepatitis viruses target just particular
organs or cells. Along with some monocytes and central nervous system cells,
HIV can pass through the plasma membranes of a subtype of lymphocytes
known T-helper cells. Attacking liver cells is the hepatitis virus. These viruses
can enter these cells since their surfaces feature binding sites unique to and
compatible with some viruses (Figure 5.6). Other recognition sites on the
surface of the virus engage the human immune system and cause the body to
generate antibodies. Made in response to the antigens or proteins linked to
invasive diseases, or in response to foreign cells—as might happen following an
organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
Glycoprotein and glycolipid patterns on the surfaces of cells provide many
viruses with a means of entrance. In the human body, HIV and hepatitis viruses
target just particular organs or cells. Along with some monocytes and central
nervous system cells, HIV can pass through the plasma membranes of a subtype
of lymphocytes known T-helper cells. Attacking liver cells is the hepatitis virus.
These viruses can enter these cells since their surfaces feature binding sites
unique to and compatible with some viruses (Figure 5.6). Other recognition
sites on the surface of the virus engage the human immune system and cause the
body to generate antibodies. Made in response to the antigens or proteins linked
to invasive diseases, or in response to foreign cells—as might happen following
an organ transplant—antibodies are created. These similar locations allow
antibodies to attach and either stop or reduce the action of the virus.
Unfortunately, mutations allow these recognition sites on HIV to change
quickly, which makes an efficient vaccination against the virus quite
challenging as the virus develops and adapts. An HIV-infected person will
rapidly acquire several populations, or varieties, of the virus that varies in these
recognition sites. Because the antibodies will not identify the new alterations in
surface markers, this fast shift of surface markers reduces the efficacy of the
person's immune system in attacking the virus. In the case of HIV, the issue is
exacerbated since the virus especially targets and kills immune response-related
cells, therefore rendering the host even more disabled.
